Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 25:10:1705-1711.
doi: 10.2147/CMAR.S165804. eCollection 2018.

A retrospective study of concurrent chemoradiotherapy plus S-1 adjuvant chemotherapy on curative effect for treatment of patients with N3 stage nasopharyngeal carcinoma

Shuai Zhang  1 , Liya Zhou  1 , Xiaopeng Huang  1 , Shaomin Lin  1
Affiliations

A retrospective study of concurrent chemoradiotherapy plus S-1 adjuvant chemotherapy on curative effect for treatment of patients with N3 stage nasopharyngeal carcinoma

Shuai Zhang et al. Cancer Manag Res. .

Abstract

Introduction: The purpose of this study was to analyze the efficacy and safety of concurrent chemoradiotherapy plus S-1 adjuvant chemotherapy for N3 stage nasopharyngeal carcinoma (NPC).

Methods: This study included 44 N3 stage NPC patients treated with concurrent chemoradiotherapy plus S-1 adjuvant chemotherapy. The intensity-modulated radiation therapy doses were planning target volume (PTV) 70-72 Gy for gross disease in the nasopharynx and 66-70 Gy for positive lymph nodes. The doses for high-risk- and low-risk region PTV were 60-62 and 54-56 Gy in 31-33 fractions. All patients received a concurrent chemotherapy program consisting of cisplatin 100 mg/m2, day 1, and the cycle repetition was every 21 days. The adjuvant chemotherapy program consisted of 4 cycles of S-1. The dose of S-1 was determined according to the body surface area (BSA): 40 mg twice a day for BSA <1.25 m2; 50 mg twice a day for 1.25 m2≤BSA<1.5 m2; and 60 mg twice a day for BSA ≥1.5 m2. S-1 was given on days 1-28, given 6 weeks apart.

Results: All 44 patients completed at least 2 cycles of concurrent chemotherapy and 4 cycles of adjuvant chemotherapy. The total efficiency of therapy was 100.0%. The 3-year overall survival (OS), distant metastasis-free survival (DMFS), local-regional control, and progression-free survival rates were 86.4%, 84.1%, 97.7%, and 81.8%, respectively. There were no differences in the OS, DMFS, and efficiency between fast-fading group (reaching partial response before the second cycle of concurrent chemotherapy) and general-fading group (the rest of the group). The incidence of rash in the entire group was low, and there was also no association with prognosis.

Conclusion: In patients with N3 stage NPC, concurrent chemoradiotherapy plus S-1 adjuvant chemotherapy yielded an excellent survival benefit, and the toxicities were mild and tolerable. Distant metastasis was the main cause of treatment failure.

Keywords: S-1; chemotherapy; intensity-modulated radiotherapy; nasopharyngeal carcinoma; prognosis.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Kaplan–Meier estimate of overall survival for N3 stage nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy plus S-1 adjuvant chemotherapy.
Figure 2
Figure 2
Kaplan–Meier estimate of distant metastasis-free survival for N3 stage nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy plus S-1 adjuvant chemotherapy.
Figure 3
Figure 3
Kaplan–Meier estimate of locoregional control for N3 stage nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy plus S-1 adjuvant chemotherapy.
Figure 4
Figure 4
Kaplan–Meier estimate of progression-free survival for N3 stage nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy plus S-1 adjuvant chemotherapy.
See this image and copyright information in PMC

References

    1. Liang X, Yang J, Gao T, et al. Nasopharynx Cancer Epidemiology in China. China Cancer. 2016;25(11):835–840. Chinese.
    1. Zong J, Lin S, Lin J, et al. Impact of intensity-modulated radiotherapy on nasopharyngeal carcinoma: validation of the 7th edition AJCC staging system. Oral Oncol. 2015;51(3):254–259. - PubMed
    1. Guo Q, Pan J, Zong J, et al. Suggestions for lymph node classification of UICC/AJCC staging system: a retrospective study based on 1197 nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy. Medicine (Baltimore) 2015;94(20):e808. - PMC - PubMed
    1. Hsu C, Lee SH, Ejadi S, et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol. 2017;35(36):4050–4056. - PubMed
    1. Strati A, Koutsodontis G, Papaxoinis G, et al. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. Ann Oncol. 2017;28(8):1923–1933. - PubMed

LinkOut - more resources